| 12.22 0.77 (6.72%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.42 |
1-year : | 16.84 |
| Resists | First : | 12.35 |
Second : | 14.42 |
| Pivot price | 9.49 |
|||
| Supports | First : | 8.56 |
Second : | 6.21 |
| MAs | MA(5) : | 10.22 |
MA(20) : | 9.25 |
| MA(100) : | 6.29 |
MA(250) : | 3.55 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 92.3 |
D(3) : | 74.3 |
| RSI | RSI(14): 80.6 |
|||
| 52-week | High : | 12.35 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLYM ] has closed above the upper band by 20.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 73.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.36 - 12.39 | 12.39 - 12.43 |
| Low: | 11.21 - 11.25 | 11.25 - 11.3 |
| Close: | 12.14 - 12.21 | 12.21 - 12.28 |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Tue, 05 May 2026
Climb Bio reports B-cell depletion data for budoprutug trial By Investing.com - Investing.com South Africa
Tue, 05 May 2026
CLYM: Budoprutug shows strong potential in immune-mediated diseases, with pivotal data expected in 2026 - TradingView
Tue, 05 May 2026
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Yahoo Finance
Tue, 05 May 2026
Drug shot matched IV B-cell depletion in Climb Bio study; June data next - Stock Titan
Tue, 05 May 2026
Climb Bio shares positive topline SC budoprutug data, ITP readout June, pMN & SLE readouts Q4 2026 - TradingView
Tue, 05 May 2026
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 63.4 (%) |
| Shares Short | 1,610 (K) |
| Shares Short P.Month | 1,800 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.1 % |
| Return on Equity (ttm) | -32.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -13.89 |
| PEG Ratio | 0 |
| Price to Book value | 3.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|